Results 251 to 260 of about 1,512,902 (358)

Genome-Wide Exploration of Thiamin Pyrophosphate Riboswitches in Medically Relevant Fungi Reveals Diverse Distribution and Implications for Antimicrobial Drug Targeting. [PDF]

ACS Omega
Vargas-Junior V, Guimarães ACR, Caffarena ER, Antunes D.   +3 more
europepmc   +1 more source

Identification of prognostic biomarkers and drug target prediction for colon cancer according to a competitive endogenous RNA network

, 2020
Daojun Hu, Boke Zhang, Miao Yu, Wenjie Shi, Li Zhang   +4 more
openalex   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Multiple Myeloma Cells with Increased Proteasomal and ER Stress Are Hypersensitive to ATX-101, an Experimental Peptide Drug Targeting PCNA. [PDF]

Cancers (Basel)
Olaisen C, Røst LM, Sharma A, Søgaard CK, Khong T, Berg S, Jang M, Nedal A, Spencer A, Bruheim P, Otterlei M.   +10 more
europepmc   +1 more source

Placental targeted drug delivery: a review of recent progress

Lin-Jian Wang, Qiaoqiao Mu, Wenjing Zhang, Weiqian Zheng, Xiaojun Zhu, Ying Yu, Yupeng Wang, Wenli Xu, Zhimin Lu, Xiujun Han   +9 more
openalex   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Combination of Betulinic Acid Fragments and Carbonic Anhydrase Inhibitors-A New Drug Targeting Approach. [PDF]

Pharmaceutics
Bache M, Heise NV, Thiel A, Funtan A, Seifert F, Petrenko M, Güttler A, Brandt S, Mueller T, Vordermark D, Thondorf I, Csuk R, Paschke R.   +12 more
europepmc   +1 more source

Validation guidelines for drug-target prediction methods [PDF]

Ziaurrehman Tanoli, Aron Schulman, Tero Aittokallio   +2 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. [PDF]

J Immunother Cancer
Ng II, Zhang J, Tian T, Peng Q, Huang Z, Xiao K, Yao X, Ng L, Zeng J, Tang H.   +9 more
europepmc   +1 more source